Emerging drugs for the treatment of bladder storage dysfunction
Andersson, Karl Erik LU
(2022)
In Expert Opinion on Emerging Drugs
27(3).
p.277-287
- Abstract
Introduction: Current drug treatment of lower urinary tract disorders, for example, overactive bladder syndrome and lower urinary tract symptoms associated with benign prostatic hyperplasia, is moderately effective, has a low treatment persistence and some short- and long-term adverse events. Even if combination therapy with approved drugs may offer advantages in some patients, there is still a need for new agents. Areas covered: New b3-adrenoceptor agonists, antimuscarinics, the naked Maxi-K channel gene, a novel 5HT/NA reuptake inhibitor and soluble guanylate cyclase activators are discussed. Focus is given to P2X3 receptor antagonists, small molecule blockers of TRP channels, the roles of cannabis on incontinence in... (More)
Introduction: Current drug treatment of lower urinary tract disorders, for example, overactive bladder syndrome and lower urinary tract symptoms associated with benign prostatic hyperplasia, is moderately effective, has a low treatment persistence and some short- and long-term adverse events. Even if combination therapy with approved drugs may offer advantages in some patients, there is still a need for new agents. Areas covered: New b3-adrenoceptor agonists, antimuscarinics, the naked Maxi-K channel gene, a novel 5HT/NA reuptake inhibitor and soluble guanylate cyclase activators are discussed. Focus is given to P2X3 receptor antagonists, small molecule blockers of TRP channels, the roles of cannabis on incontinence in patients with multiple sclerosis, and of drugs acting directly on CB1 and CB2 receptor or indirectly via endocannabinoids by inhibition of fatty acid aminohydrolase. Expert opinion: New potential alternatives to currently used drugs/drug principles are emerging, but further clinical testing is required before they can be evaluated as therapeutic alternatives. It seems that for the near future individualized treatment with approved drugs and their combinations will be the prevailing therapeutic approach.
(Less)
- author
- Andersson, Karl Erik
LU
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cannabinoids, lower urinary tract symptoms, overactive bladder, P2X3 receptor antagonists, sGC activators, TRP channel blockers
- in
- Expert Opinion on Emerging Drugs
- volume
- 27
- issue
- 3
- pages
- 11 pages
- publisher
- Ashley Publications
- external identifiers
-
- pmid:35975727
- scopus:85136193010
- ISSN
- 1472-8214
- DOI
- 10.1080/14728214.2022.2113057
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
- id
- f2032cda-fb82-46ca-9195-6516c6b27ff9
- date added to LUP
- 2022-09-07 15:17:14
- date last changed
- 2024-06-27 20:32:39
@article{f2032cda-fb82-46ca-9195-6516c6b27ff9,
abstract = {{<p>Introduction: Current drug treatment of lower urinary tract disorders, for example, overactive bladder syndrome and lower urinary tract symptoms associated with benign prostatic hyperplasia, is moderately effective, has a low treatment persistence and some short- and long-term adverse events. Even if combination therapy with approved drugs may offer advantages in some patients, there is still a need for new agents. Areas covered: New b<sub>3</sub>-adrenoceptor agonists, antimuscarinics, the naked Maxi-K channel gene, a novel 5HT/NA reuptake inhibitor and soluble guanylate cyclase activators are discussed. Focus is given to P2X3 receptor antagonists, small molecule blockers of TRP channels, the roles of cannabis on incontinence in patients with multiple sclerosis, and of drugs acting directly on CB1 and CB2 receptor or indirectly via endocannabinoids by inhibition of fatty acid aminohydrolase. Expert opinion: New potential alternatives to currently used drugs/drug principles are emerging, but further clinical testing is required before they can be evaluated as therapeutic alternatives. It seems that for the near future individualized treatment with approved drugs and their combinations will be the prevailing therapeutic approach.</p>}},
author = {{Andersson, Karl Erik}},
issn = {{1472-8214}},
keywords = {{Cannabinoids; lower urinary tract symptoms; overactive bladder; P2X3 receptor antagonists; sGC activators; TRP channel blockers}},
language = {{eng}},
number = {{3}},
pages = {{277--287}},
publisher = {{Ashley Publications}},
series = {{Expert Opinion on Emerging Drugs}},
title = {{Emerging drugs for the treatment of bladder storage dysfunction}},
url = {{http://dx.doi.org/10.1080/14728214.2022.2113057}},
doi = {{10.1080/14728214.2022.2113057}},
volume = {{27}},
year = {{2022}},
}